Table 2.

Results of the segmented regression analysis for drug utilisation*

		Time		Drug price reduction		Time after drug price reduction		New guideline		Time after new guideline
	Group	Estimate	p Value	Estimate	p Value	Estimate	p Value	Estimate	p Value	Estimate	p Value
Daily drug utilisation	All	−0.0016	<0.001	0.0018	0.225	0.0015	<0.001	0.0035	0.026	−0.0038	<0.001
	Health insurance	−0.0016	<0.001	0.0022	0.143	0.0015	<0.001	0.0027	0.104	−0.0037	<0.001
	Medical aid	−0.0014	0.147	−0.0040	0.628	0.0007	0.689	0.0181	0.006	−0.0062	0.002
Average number of drugs per month	All	0.0047	<0.001	−0.0265	<0.001	0.0016	<0.001	−0.0073	0.004	−0.0171	<0.001
	Health insurance	0.0048	<0.001	−0.0263	<0.001	0.0016	<0.001	−0.0100	<0.001	−0.0169	<0.001
	Medical aid	0.0035	0.007	−0.0332	0.003	0.0012	0.566	0.0352	<0.001	−0.0204	<0.001
Per cent of original drugs (%)	All	−0.0958	<0.001	−0.0457	0.557	0.0156	0.454	0.0460	0.535	0.0193	0.373
	Health insurance	−0.0971	<0.001	−0.0416	0.603	0.0211	0.322	0.0548	0.476	0.0064	0.774
	Medical aid	−0.1001	0.098	−0.0657	0.849	−0.0470	0.637	−0.1195	0.679	0.1951	0.091

*All results were adjusted by age, sex, region, insurance type, Charlson comorbidity index and combinations of hypertension agents.